Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.60 |
| ▸ | CASR | P41180 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11034979 | 0.89 | EPHX1 (0.68) | EPHX1 | |
| SCHEMBL11035964 | 0.89 | EPHX1 (0.68) | EPHX1 | |
| SCHEMBL24011409 | 0.89 | CASR (0.59) | CASRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26633938 | 0.89 | CASR (0.62) | CASRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11366053 | 0.85 | EPHX1 (0.61) | EPHX1 | |
| SCHEMBL11360702 | 0.85 | EPHX1 (0.61) | EPHX1 | |
| SCHEMBL24576223 | 0.84 | NPC1 (0.71) | CASRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22221566 | 0.84 | EPHX2 (0.71) | SMN1; SMN2 | |
| SCHEMBL7269061 | 0.84 | EPHX1 (0.59) | CNR1CNR2EPHX1 | |
| SCHEMBL7271441 | 0.84 | EPHX1 (0.59) | CNR1CNR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | CNR1 1017/4885CASR 2176/4885CNR2 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.